Study of Panitumumab in the Treatment of Carcinoid Syndrome
Status:
Withdrawn
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal
growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who
fail or do not adequately respond to octreotide or other supportive therapies.